Mainz Biomed NV
MYNZ
$6.79
Closing
▼-7.24%
1D
▼-85.37%
YTD
MYNZ
BBG012XZKHZ2
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$12.96M
Analysts' Rating
BUY
Price Target (Mean)
2.00
Total Analysts
3
P/E
Operating Margin
-3046.06%
Beta
Revenue Growth
0.00%
52 week high
$52.40
52 week low
$6.25
Div. Yield
%
EPS Growth
0.00
Company Profile
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
